- •The impact of concomitant drugs was investigated in patients with advanced cancer treated with immune checkpoint inhibitors.
- •We firstly tested a single-institution cohort of 217 patients with advanced cancer.
- •Corticosteroids, antibiotics and proton-pump inhibitors were related to shorter overall survival (OS).
- •We created a drug-based prognostic score predicting OS, progression-free survival and objective response rate.
- •The score was externally validated in a multicenter cohort of 1012 patients.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?.Hum Vaccines Immunother. 2020; (in press)https://doi.org/10.1080/21645515.2020.1769398
- The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy.Canc Cell. 2018; 33: 570-580https://doi.org/10.1016/j.ccell.2018.03.015
- Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?.Cancer Immunol Immunother. 2004; 53: 879-892https://doi.org/10.1007/s00262-004-0577-x
- Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer.J Clin Oncol. 2018; 36: 2872-2878https://doi.org/10.1200/JCO.2018.79.0006
- Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications.J Clin Oncol. 2019; 37: 1927-1934https://doi.org/10.1200/JCO.19.00189
- Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic Review and meta-analysis.Cancers. 2020; 12 (Published 2020 Feb 27): 546https://doi.org/10.3390/cancers12030546
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.Ann Oncol. 2018; 29: 1437-1444https://doi.org/10.1093/annonc/mdy103
- Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.Ann Oncol. 2020; 31: 525-531https://doi.org/10.1016/j.annonc.2020.01.006
- Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer.JAMA Oncol. 2019; 5 ([published online ahead of print, 2019 Sep 12] [published correction appears in JAMA Oncol. 2020 Feb 1;6(2):302]): 1774-1778https://doi.org/10.1001/jamaoncol.2019.2785
- Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.J Canc Res Clin Oncol. 2020; ([published online ahead of print, 2020 May 27])https://doi.org/10.1007/s00432-020-03252-4
- al. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice.J Immunother Cancer. 2020; 8e001361https://doi.org/10.1136/jitc-2020-001361
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Canc. 2009; 45: 228-247https://doi.org/10.1016/j.ejca.2008.10.026
- Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%.Cancer Immunol Immunother. 2020; ([published online ahead of print, 2020 May 30])https://doi.org/10.1007/s00262-020-02613-9
- Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients.Ann Oncol. 2018; 29 (40–40)https://doi.org/10.1093/annonc/mdy511.001
- The pivotal role of the dysregulation of cholesterol homeostasis in cancer: implications for therapeutic targets.Cancers. 2020; 12 (Published 2020 May 29): E1410https://doi.org/10.3390/cancers12061410
- The prognostic role of high blood cholesterol in advanced cancer patients treated with immune checkpoint inhibitors.J Immunother. 2020; 43: 196-203https://doi.org/10.1097/CJI.0000000000000321
- The impact of nonsteroidal anti-inflammatory drugs, beta blockers, and metformin on the efficacy of anti-PD-1 therapy in advanced melanoma.Oncologist. 2020; 25 (e602-e605)https://doi.org/10.1634/theoncologist.2019-0518
- Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.J Immunother Canc. 2018; 6 (Published 2018 Jul 2): 64https://doi.org/10.1186/s40425-018-0375-1
- Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma.Melanoma Res. 2016; 26: 609-615https://doi.org/10.1097/CMR.0000000000000299
- How variables uncorrelated with the dependent variable can actually make excellent predictors: the important suppressor variable case. Southwest educational research association annual meeting proceedings.1997 (Available at:)Last access on June 10th, 2020)
- Examples of easily explainable suppressor variables in multiple regression research.Mult Lin Regression Viewp. 1997; 24: 11-13
“Stopping stepwise: why stepwise selection is bad and what you should use instead”. On towardsdatascience.com website. Available at: https://towardsdatascience.com/stopping-stepwise-why-stepwise-selection-is-bad-and-what-you-should-use-instead-90818b3f52df.Last access on June 10th, 2020.
- A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.J Immunother Canc. 2019; 7 (Published 2019 Feb 27): 57https://doi.org/10.1186/s40425-019-0527-y
- Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of immune-related adverse events.Eur J Canc. 2020; 128 ([published online ahead of print, 2020 Feb 4]): 17-26https://doi.org/10.1016/j.ejca.2019.12.031
- Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab.Immunotherapy. 2018; 10: 681-694https://doi.org/10.2217/imt-2017-0175
- External validation is necessary in prediction research: a clinical example.J Clin Epidemiol. 2003 Sep; 56: 826-832https://doi.org/10.1016/s0895-4356(03)00207-5
- Improved comorbidity adjustment for predicting mortality in Medicare populations.Health Serv Res. 2003; 38: 1103-1120https://doi.org/10.1111/1475-6773.00165
- Regression coefficient-based scoring system should be used to assign weights to the risk index.J Clin Epidemiol. 2016; 79: 22-28https://doi.org/10.1016/j.jclinepi.2016.03.031
- Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.J Immunother Canc. 2018; 6 (Published 2018 Apr 4): 26https://doi.org/10.1186/s40425-018-0336-8
- Impact of patients’ gender on efficacy of immunotherapy in patients with metastatic kidney cancer: a systematic Review and meta-analysis.Clin Genitourin Canc. 2020; 18 (88–94.e2)https://doi.org/10.1016/j.clgc.2019.09.004
- Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.Oncotarget. 2017; 8 (Published 2017 Jun 28): 93149-93155https://doi.org/10.18632/oncotarget.18703
- Chronic glucocorticoid treatment induced circadian clock disorder leads to lipid metabolism and gut microbiota alterations in rats.Life Sci. 2018; 192: 173-182https://doi.org/10.1016/j.lfs.2017.11.049
- Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases.Inflamm Bowel Dis. 2015; 21: 963-972https://doi.org/10.1097/MIB.0000000000000332
- Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome.PloS One. 2010; 5 (Published 2010 Mar 24): e9836https://doi.org/10.1371/journal.pone.0009836
- Antibiotics-driven gut microbiome perturbation alters immunity to vaccines in humans.Cell. 2019; 178 (1313–1328.e13)https://doi.org/10.1016/j.cell.2019.08.010
- Proton pump inhibitors alter the composition of the gut microbiota.Gut. 2016; 65: 749-756https://doi.org/10.1136/gutjnl-2015-310861
- The impact of proton pump inhibitors on the human gastrointestinal microbiome.Clin Lab Med. 2014; 34: 771-785https://doi.org/10.1016/j.cll.2014.08.008
- The effect of omeprazole on the development of experimental autoimmune encephalomyelitis in C57BL/6J and SJL/J mice.BMC Res Notes. 2014; 7 (Published 2014 Sep. 4): 605https://doi.org/10.1186/1756-0500-7-605
- Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.Science. 2018; 359: 91-97https://doi.org/10.1126/science.aan3706
- Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications.BMC Canc. 2020; 20 (Published 2020 May 6): 383https://doi.org/10.1186/s12885-020-06882-6
- The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal.Eur J Intern Med. 2017; 37: 19-24https://doi.org/10.1016/j.ejim.2016.10.007
- The urinary microbiome and anticancer immunotherapy: the potentially hidden role of unculturable microbes.Target Oncol. 2019; 14: 247-252https://doi.org/10.1007/s11523-019-00643-7